Vykoura is a drug owned by Avyxa Holdings Llc. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 23, 2044. Details of Vykoura's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12564592 | NA |
Dec, 2044
(18 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Vykoura is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Vykoura's family patents as well as insights into
ongoing legal events
on those patents.
Vykoura's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vykoura's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 23, 2044 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vykoura Generic API suppliers:
Leucovorin Calcium is the generic name for the brand Vykoura. 26 different companies have already filed for the generic of Vykoura, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vykoura's generic
Alternative Brands for Vykoura
There are several other brand drugs using the same active ingredient (Leucovorin Calcium) as Vykoura. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Acrotech Biopharma |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Leucovorin Calcium, Vykoura's active ingredient. Check the complete list of approved generic manufacturers for Vykoura
About Vykoura
Vykoura is a drug owned by Avyxa Holdings Llc. Vykoura uses Leucovorin Calcium as an active ingredient. Vykoura was launched by Avyxa in 2026.
Approval Date:
Vykoura was approved by FDA for market use on 03 February, 2026.
Active Ingredient:
Vykoura uses Leucovorin Calcium as the active ingredient. Check out other Drugs and Companies using Leucovorin Calcium ingredient
Dosage:
Vykoura is available in solution form for intramuscular, intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 350MG BASE/35ML (EQ 10MG BASE/ML) | SOLUTION | Prescription | INTRAMUSCULAR, INTRAVENOUS |
| EQ 500MG BASE/50ML (EQ 10MG BASE/ML) | SOLUTION | Prescription | INTRAMUSCULAR, INTRAVENOUS |
| EQ 50MG BASE/5ML (EQ 10MG BASE/ML) | SOLUTION | Prescription | INTRAMUSCULAR, INTRAVENOUS |